Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)

Detalhes bibliográficos
Autor(a) principal: Silva-Costa, Catarina
Data de Publicação: 2022
Outros Autores: Silva, Joana, Pinho, Marcos Daniel, Friães, Ana, Ramirez, Mário, Cristino, José Melo, Oliveira, Laura Andrade de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/54404
Resumo: Copyright © 2022 Silva-Costa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
id RCAP_3e466ebd3e25eb72c94632dd249a53cb
oai_identifier_str oai:repositorio.ul.pt:10451/54404
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)Streptococcus pneumoniaeDiagnosticsEpidemiologyNucleic acid technologyPediatric infectious diseasePneumoniaSerotypesVaccinesCopyright © 2022 Silva-Costa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.We previously reported that despite the use of pneumococcal conjugate vaccines (PCVs), vaccine serotypes remained important causes of pneumonia with pleural effusion and empyema (pediatric complicated pneumococcal pneumonia [PCPP]). We cultured and performed PCR on 174 pleural fluid samples recovered from pediatric patients in Portugal from 2016 to 2019 to identify and serotype Streptococcus pneumoniae. Most PCPP cases (n = 87/98) were identified by PCR only. Serotypes 3 (67%), 14, and 8 (5% each) were the most frequent. Vaccine breakthrough cases were seen among age-appropriately, 13-valent, PCV vaccinated children (median: 3 years, range: 17 months to 7 years), mostly with serotype 3 (n = 27) but also with serotypes 14 and 19A (n = 2 each). One breakthrough was seen with serotype 14 in an age-appropriately, 10-valent, PCV-vaccinated child and another with serotype 3 in a child to whom the 23-valent polysaccharide vaccine was administered. While the relative risk of serotype 1 PCPP decreased almost 10-fold from the period of 2010 to 2015 to the period of 2016 to 2019 (relative risk [RR] = 0.106), that of serotype 3 PCPP almost doubled (RR = 1.835). Our data highlight the importance of molecular diagnostics in identifying PCPP and document the continued importance of serotype 3 PCPP, even when PCV13 use with almost universal coverage could be expected to reduce exposure to this serotype. IMPORTANCE The use of conjugate vaccines against Streptococcus pneumoniae in children has led to substantial reductions in pneumococcal invasive disease. However, the reductions seen in each of the 13 serotypes currently included in the highest-valency vaccine approved for use in children (PCV13), were not the same. It is becoming clear that most vaccine breakthroughs worldwide involve serotype 3 and are frequently associated with complicated pneumonia cases, often with empyema or pleural effusion. Here, we show that despite almost universal PCV13 use, which would be expected to reduce vaccine serotype circulation and further reinforce vaccine direct protection, pneumococci and serotype 3 remain the major causes of pediatric complicated pneumonia. Molecular methods are essential to identify and serotype pneumococci in these cases, which frequently reflect vaccine breakthroughs. A broader use of molecular diagnostics will be essential to determine the role of this important serotype in the context of PCV13 use in different geographic regions.Partial support was received from the Fundação para a Ciência e a Tecnologia (PTDC/DTP-EPI/1555/2014) and from an investigator-initiated grant from Pfizer.American Society for MicrobiologyRepositório da Universidade de LisboaSilva-Costa, CatarinaSilva, JoanaPinho, Marcos DanielFriães, AnaRamirez, MárioCristino, José MeloOliveira, Laura Andrade de2022-09-09T11:21:22Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/54404engMicrobiol Spectr. 2022 Aug 31;10(4):e010772210.1128/spectrum.01077-222165-0497info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:00:42Zoai:repositorio.ul.pt:10451/54404Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:05:11.374801Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
title Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
spellingShingle Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
Silva-Costa, Catarina
Streptococcus pneumoniae
Diagnostics
Epidemiology
Nucleic acid technology
Pediatric infectious disease
Pneumonia
Serotypes
Vaccines
title_short Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
title_full Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
title_fullStr Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
title_full_unstemmed Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
title_sort Continued vaccine breakthrough cases of serotype 3 complicated pneumonia in vaccinated children, Portugal (2016–2019)
author Silva-Costa, Catarina
author_facet Silva-Costa, Catarina
Silva, Joana
Pinho, Marcos Daniel
Friães, Ana
Ramirez, Mário
Cristino, José Melo
Oliveira, Laura Andrade de
author_role author
author2 Silva, Joana
Pinho, Marcos Daniel
Friães, Ana
Ramirez, Mário
Cristino, José Melo
Oliveira, Laura Andrade de
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Silva-Costa, Catarina
Silva, Joana
Pinho, Marcos Daniel
Friães, Ana
Ramirez, Mário
Cristino, José Melo
Oliveira, Laura Andrade de
dc.subject.por.fl_str_mv Streptococcus pneumoniae
Diagnostics
Epidemiology
Nucleic acid technology
Pediatric infectious disease
Pneumonia
Serotypes
Vaccines
topic Streptococcus pneumoniae
Diagnostics
Epidemiology
Nucleic acid technology
Pediatric infectious disease
Pneumonia
Serotypes
Vaccines
description Copyright © 2022 Silva-Costa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-09T11:21:22Z
2022
2022-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/54404
url http://hdl.handle.net/10451/54404
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Microbiol Spectr. 2022 Aug 31;10(4):e0107722
10.1128/spectrum.01077-22
2165-0497
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134603437408256